Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

EU Approves Abiraterone for Newly Diagnosed Hormone-Sensitive Prostate Cancer

November 22nd 2017

The European Commission has approved abiraterone acetate (Zytiga) in combination with prednisone/prednisolone for the treatment of adult men with newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer.

Dr. Inman on Immunotherapy Combinations in Bladder Cancer

November 21st 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Optimizing Adjuvant Therapy in Renal Cell Carcinoma

November 20th 2017

Patients with high-risk renal cell carcinoma who harbor early systemic dissemination with very poor survival prognosis may derive some benefit from adjuvant therapy.

Immunotherapy Continues to Shape Future Bladder Cancer Paradigm

November 20th 2017

Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.

Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney Cancer

November 19th 2017

Umberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.

Dr. Powles on the Impact of Immunotherapy in Kidney Cancer

November 19th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

Incentivizing the Lower-Cost Decision: LUGPA Believes It Knows How

November 19th 2017

A newly proposed urology-specific alternative payment model could save up to 37% on costs of care, partly by giving physicians incentives to pursue active surveillance rather than active intervention, according to the Large Urology Group Practice Association.

Next Steps in Bladder Cancer to Include Combination Immunotherapy

November 19th 2017

Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.

Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC

November 18th 2017

Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.

Dr. Junker on Need to Identify Biomarkers to Predict Response to RCC Treatment

November 18th 2017

Kerstin Junker, MD, associate professor, Department of Urology, Universit

Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC

November 18th 2017

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.

Dr. Volpe Discusses the Management of Localized Kidney Cancer

November 18th 2017

Alessandro Volpe, MD, University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, discusses the management of locally advanced kidney cancer.

Pembrolizumab, Atezolizumab New Standards for Bladder Cancer

November 18th 2017

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

Combining Partial Metastasectomy With Systemic Treatment Beneficial in mRCC

November 18th 2017

The addition of incomplete metastasectomy to systemic therapy improved median overall survival by 3 months in patients with metastatic renal cell carcinoma.

Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer

November 17th 2017

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

Dr. Lara on the FDA Approval of Adjuvant Sunitinib in RCC

November 17th 2017

Primo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).

FDA Approves Adjuvant Sunitinib for High-Risk RCC

November 17th 2017

The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.

Cabozantinib RCC Benefit Highlighted as Frontline Approval Approaches

November 16th 2017

Cabozantinib (Cabometyx) remains to be the sole oral drug to meet 3 clinical trial endpoints of progression-free survival, overall survival, and overall response rate in patients with advanced RCC.

Dr. Galsky on Resistance to Checkpoint Blockade in Metastatic Bladder Cancer

November 15th 2017

Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.

Prostate Cancer Paradigm Expanding With Ongoing Research

November 15th 2017

Przemyslaw W. Twardowski, MD, discusses a variety of factors to consider when treating patients with prostate cancer.